These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 22201408)

  • 1. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
    Kilickap S; Oztoprak I; Yucel B
    Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
    Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
    Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab and daily temozolomide for recurrent glioblastoma.
    Desjardins A; Reardon DA; Coan A; Marcello J; Herndon JE; Bailey L; Peters KB; Friedman HS; Vredenburgh JJ
    Cancer; 2012 Mar; 118(5):1302-12. PubMed ID: 21792866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.
    Fellah S; Girard N; Chinot O; Cozzone PJ; Callot V
    J Clin Oncol; 2011 Apr; 29(11):e308-11. PubMed ID: 21263101
    [No Abstract]   [Full Text] [Related]  

  • 6. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
    Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
    J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superselective intra-arterial cerebral infusion of novel agents after blood-brain disruption for the treatment of recurrent glioblastoma multiforme: a technical case series.
    Shin BJ; Burkhardt JK; Riina HA; Boockvar JA
    Neurosurg Clin N Am; 2012 Apr; 23(2):323-9, ix-x. PubMed ID: 22440875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
    Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
    Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.
    Sepúlveda JM; Belda-Iniesta C; Gil-Gil M; Pérez-Segura P; Berrocal A; Reynés G; Gallego O; Capellades J; Ordoñez JM; La Orden B; Balañá C
    Clin Transl Oncol; 2015 Sep; 17(9):743-50. PubMed ID: 26033428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
    Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
    Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab plus irinotecan in recurrent glioblastoma.
    Chamberlain MC
    J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
    [No Abstract]   [Full Text] [Related]  

  • 13. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab.
    Gerstner ER; Frosch MP; Batchelor TT
    J Clin Oncol; 2010 Feb; 28(6):e91-3. PubMed ID: 19933906
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
    Friedman GK; Spiller SE; Harrison DK; Fiveash JB; Reddy AT
    J Pediatr Hematol Oncol; 2013 Apr; 35(3):e123-6. PubMed ID: 23425999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
    Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
    Lou E; Turner S; Sumrall A; Reardon DA; Desjardins A; Peters KB; Sampson JH; Friedman HS; Vredenburgh JJ
    J Clin Oncol; 2011 Oct; 29(28):e739-42. PubMed ID: 21900098
    [No Abstract]   [Full Text] [Related]  

  • 17. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 18. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
    Tonder M; Eisele G; Weiss T; Hofer S; Seystahl K; Valavanis A; Stupp R; Weller M; Roth P
    Acta Oncol; 2014 Oct; 53(10):1436-40. PubMed ID: 24862539
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience.
    Kaloshi G; Brace G; Rroji A; Bushati T; Roci E; Hoxha M; Fejzo G; Petrela M
    Tumori; 2013; 99(5):601-3. PubMed ID: 24362864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.